|
Other Liabilities
|
3 Months Ended | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Oct. 31, 2013
|
|||||||||||||||||||||||||||||||||||||
| Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract] | |||||||||||||||||||||||||||||||||||||
| Other Liabilities Disclosure [Text Block] |
Note 8 – Other Liabilities Other liabilities consist of the following as of:
During the three months ended October 31, 2013, the Company entered into various installment loans for lab and transportation equipment aggregating $115 for the Clinical Labs segment. As of October 31, 2013, future minimum payments under the capital lease, net of interest of $70 aggregates $619, including a short term debt portion of $149 included in other current liabilities. Future minimum payments under the installment loans aggregate $505, including a short term portion of $200 included in other current liabilities. |
||||||||||||||||||||||||||||||||||||